Inhibition of peritoneal metastasis in an animal gastric cancer model by interferon-γ and interleukin-2

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 149-153

  Okamoto, Takahide ^a   Tsuburaya, Akira ^b   Yanoma, Syunsuke ^b   Yoshikawa, Takaki ^c   Cho, Haruhiko ^b   Takanashi, Yoshinori ^a   Noguchi, Yoshikazu ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c Yokohama Kowan Hospital   (Japan)

Author keywords

Gastric cancer; Interferon ; Interleukin 2; Peritoneal metastasis

Indexed keywords

INTERLEUKIN 2; RECOMBINANT GAMMA INTERFERON; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; MICE; MICE, INBRED ICR; MICE, NUDE; PERITONEAL NEOPLASMS; RANDOM ALLOCATION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0345700297     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parkin DM, Laara E and Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41: 184-197, 1988.
2. Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS and Brennan MF: Is gastric carcinoma different between Japan and the United States? Cancer 89: 2237-2246, 2000.
3. Shu RY, Su HL, Yu JC and Jiang SY: Direct growth suppresive, activity of interferon-α and γ on human gastric cancer cells. J Surg Oncol 75: 122-130, 2000.
4. Kubota T, Kase S and Otani Y et al: Interferon-2α and β increase the antitumor activity, detected by MTT assay, of 5-fluorouracil against experimental and clinical human gastrointestinal carcinomas. Anticancer Res 17: 725.-728, 1997.
5. Kurzrock R, Gutterman JU and Talpaz M: Interferons α, β, γ; Basic Principles and Preclinical Studies in Biologic Therapy of Cancer. Lippincott, Philadelphia: 247-274, 1991.
6. Kuribayashi K, Gillis S, Kem DE and Henney CS: Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 126: 2321-2327, 1981.
7. Yamaguchi Y, Satoh Y, Miyahara E et al.: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15: 2201-6, 1995.
8. Douglas A, Weight GH and Howard M J: Interleukin-2 enhances natural killer cell activity through induction or Gamma Interferon. Infect Immunol 41: 992-997, 1983.
9. Herrmann M, Lorenz HM and Voll R et al.: A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22: 5506-5507, 1994.
10. Vedantham S, Gamliel H and Golimb HM: Mechanism of interferon action in hairy cell leukemia: A model of effective cancer biotherapy Cancer Res 52: 1056-1066, 1992.
11. Borden EC and Ball LA: Interferons: biochemical, cell growth inhibitory and immunologicaI effects. Prog Hematol 12: 299-339, 1981.
12. Ugurel S, Seiter S, Rappl G et al.: Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with Bcl-2 and Bcl-X expression and is sensitive to modulation by interferon-γ. Int J Cancer 82: 727-736, 1999.
13. Ing DJ, Zang J, Dzau VJ et al.: Modulation of cytokine-induced cardiac myocyte apoptosis by nitrite oxide. Circ Res 84: 21-33, 1999.
14. Deiss LP, Falinka H, Berissi H et al.: Cathepsin D protease mediates programmed cell death induced by interferon-γ, Fas/APO1, and TNF-α. EMBO J 15: 3861-3870, 1996.
15. Gender J, Lemke H and Baisch H et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
16. Aiyer AR, Serrano LE and Jones PP: Interferon-γ binds to high and low affinity receptor components on murine macrophages. J Immunol 136: 3329-3334, 1986.
17. Han X, Wilbanks GD, Devaja O, Ruperelia V and K Raju KS: IL-2 enhances standard IFN-γ/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Gynecolo Oncol 75: 198-210, 1999.
18. Hennery CS, Kuribayashi K, Kern DE et al: Interleukin-2 augments natural killer cells activity. Nature 291: 335-338, 1981.